Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
about
An ETP model (exclusion-tolerance-progression) for multi drug resistanceResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53Estimation of glomerular filtration rate in cancer patientsPopulation pharmacokinetics and pharmacodynamics of oral etoposideDose schedule optimization and the pharmacokinetic driver of neutropeniaEvaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events.Translational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.Current management of epithelial ovarian carcinoma: a review.Comparison of two methods for carboplatin dosing in children with retinoblastoma.A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapyNanocarriers for delivery of platinum anticancer drugs.Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.Carboplatin dosing for adult Japanese patients.The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.Pharmacokinetics of high-dose chemotherapy.Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.A study of Docetaxel-induced effects in MCF-7 cells by means of Raman microspectroscopy.The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumoursPharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyAdaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Therapeutic drug monitoring of cancer chemotherapy.Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-HThe Renaissance of platinum-based chemotherapy for metastatic breast cancer.Drug exposure: still an excellent biomarker.Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.Personalised dosing of medicines for children.Carboplatin therapeutic monitoring in preterm and full-term neonates.Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance.Novel algorithm for more accurate calculation of renal function in adults with cancer.
P2860
Q24805788-C2066B2C-F2BC-49F2-8AB9-4FD0ED117478Q27006998-36ECEF1A-3083-466A-9C54-EF345C8D0358Q28350826-A0D43B54-DD9C-4E33-87B8-C3A7E1376C5FQ28365888-6F1D66C3-EFCC-4A62-8B1C-97BC899CF8E3Q28544635-3558F8E2-9446-4B43-A44C-9D02B0C8AAC4Q33383126-D569DA4C-220C-406B-87B7-209700B1C70AQ33431846-4932A585-B755-48D3-B913-4EA90C88AF3BQ33440695-57C6C6AB-7409-4837-95F9-045CEF87449AQ33896659-527D1747-4507-43EE-9E7D-33DC0A28E2ECQ33959810-23B7082E-9EB4-45CB-85AE-E2798F9FFA58Q34065022-96FE810D-773C-434E-A1AA-65B73CEC2DDAQ34127889-C4BB4B14-D7A4-4E44-8737-1B4DD6F33E51Q34338695-D74D8E29-E900-4A39-BBDC-71705C54A5BFQ35060593-6A124BB3-E6DB-4448-8168-AF0E60E70FF0Q35135110-E40F7322-D992-4672-9FBE-25F2DDAABDB4Q35205223-E0612177-AFE1-4BC2-8627-993C8CD95E79Q35597047-FE04A15C-7443-40E8-8A28-D3EE6C5AAA49Q35804392-83366801-03AF-4448-A0E9-8725D8040103Q35827602-47F6EA14-7C86-479E-BB4B-6121DB06F236Q35911613-7328B8BD-8B6F-434B-860A-1F67FDB12841Q35970344-1763B8B5-0B39-4960-BE9C-899D3D3933DFQ36135407-4FDD68E8-25C8-4C41-9446-3A2635293C2AQ36138637-A8946838-15B5-4E05-9ACD-CC26960F7EEFQ36431257-CBDE5FDB-B7C5-49B9-84B6-05670C7CF530Q36431475-93044155-1614-4692-8E0A-B01D91322128Q36609993-8243B795-CDE9-4D00-B670-D071EDB0C391Q36948123-026CD7C1-26D0-4833-A89F-2D3261A70682Q37018328-8571D3A7-F083-4026-8CF1-F5C4A6825AE1Q37136655-03BB09DD-035F-4E1E-88BD-D9E2552EF514Q37333198-64CD2D54-14E7-4239-B497-A4AE2A21CFCFQ37755342-E89209B4-5BA5-49C9-B0E1-E410C172CD97Q38603693-C8698CBE-EF86-4097-8015-2EFCFF35651CQ38689410-F65AADD1-9E4C-42D3-9E04-044B2F004F22Q38749764-5A139DE8-5C0A-4958-98A8-FCFD36522E71Q38978857-30DB979D-72FC-42A5-9C90-00D6AD044B00Q40662868-4DEF5326-EC31-4CA9-9822-E9CED64A4562Q40986092-3F846A46-89B1-49C6-B50A-2A10BF45C840Q43189722-596C758B-1E12-4ED3-8D7F-0425AA924980Q44046722-9D042C52-49AC-459B-AACD-0E9698DC045AQ46228860-39C5C8FB-3CC0-4422-BCE7-D45614594AAC
P2860
Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Relationships between carbopla ...... patients with ovarian cancer.
@ast
Relationships between carbopla ...... patients with ovarian cancer.
@en
type
label
Relationships between carbopla ...... patients with ovarian cancer.
@ast
Relationships between carbopla ...... patients with ovarian cancer.
@en
prefLabel
Relationships between carbopla ...... patients with ovarian cancer.
@ast
Relationships between carbopla ...... patients with ovarian cancer.
@en
P2093
P1476
Relationships between carbopla ...... patients with ovarian cancer.
@en
P2093
D I Jodrell
E P Goldbloom
E Wiltshaw
J L Goodlow
J N Burroughs
M J Egorin
P Langenberg
R M Canetta
P304
P356
10.1200/JCO.1992.10.4.520
P407
P577
1992-04-01T00:00:00Z